UZH-Logo

Maintenance Infos

Browse by Creators - Zurich Open Repository and Archive

Navigate back| Up a level
Export as
Number of items: 66.

Feilchenfeldt, J; Varga, Z; Siano, M; Grabsch, H I; Held, U; Schuknecht, B; Trip, A; Hamaguchi, T; Gut, P; Balague, O; Khanfir, K; Diebold, J; Jochum, W; Shoji, H; Kushima, R; Wagner, D; Shimada, Y; Cats, A; Knuth, A; Moch, H; Aebi, S; Hofer, S (2015). Corrigendum: Brain metastases in gastro-oesophageal adenocarcinoma: insights into the role of the human epidermal growth factor receptor 2 (HER2). British Journal of Cancer, 113(12):1747.

Feilchenfeldt, J; Varga, Z; Siano, M; Grabsch, H I; Held, U; Schuknecht, B; Trip, A; Hamaguchi, T; Gut, P; Balague, O; Khanfir, K; Diebold, J; Jochum, W; Shoji, H; Kushima, R; Wagner, D; Shimada, Y; Cats, A; Knuth, A; Moch, H; Aebi, S; Hofer, S (2015). Brain metastases in gastro-oesophageal adenocarcinoma: insights into the role of the human epidermal growth factor receptor 2 (HER2). British Journal of Cancer, 113(5):716-721.

Scharl, M; Bode, B; Rushing, E; Knuth, A; Rordorf, T (2014). Uncommon case of brain metastasis in a patient with a history of heavy smoking. Current Oncology, 21(5):e728-e731.

Scharl, M; Bode, B; Rushing, E; Knuth, A; Rordorf, Tamara (2014). Uncommon case of brain metastasis in a patient with a history of heavy smoking. Current Oncology, 21:e728-731.

Jäger, E; Knuth, A (2012). The discovery of cancer/testis antigens by autologous typing with T cell clones and the evolution of cancer vaccines. Cancer Immunity, 12:6-9.

Reiner, C S; Goetti, R; Burger, I A; Fischer, M A; Frauenfelder, T; Knuth, A; Pfammatter, T; Schaefer, N; Alkadhi, H (2012). Liver perfusion imaging in patients with primary and metastatic liver malignancy: prospective comparison between 99mTc-MAA spect and dynamic CT perfusion. Academic Radiology, 19(5):613-621.

Noguchi, T; Kato, T; Wang, L; Maeda, Y; Ikeda, H; Sato, E; Knuth, A; Gnjatic, S; Ritter, G; Sakaguchi, S; Old, L J; Shiku, H; Nishikawa, H (2012). Intracellular tumor-associated antigens represent effective targets for passive immunotherapy. Cancer Research, 72(7):1672-1682.

Goetti, R; Reiner, C S; Knuth, A; Klotz, E; Stenner, F; Samaras, P; Alkadhi, H (2012). Quantitative perfusion analysis of malignant liver tumors: dynamic computed tomography and contrast-enhanced ultrasound. Investigative Radiology, 47(1):18-24.

Reiner, C S; Goetti, R; Burger, I A; Fischer, M A; Frauenfelder, T; Knuth, A; Pfammatter, T; Schaefer, N; Alkadhi, H (2012). Liver Perfusion Imaging in Patients with Primary and Metastatic Liver Malignancy Prospective Comparison between (99m)Tc -MAA SPECT and Dynamic CT Perfusion. Academic Radiology, 19(5):613-621.

Oehler, C; Frei, K; Rushin, E J; McSheehy, P M J; Weber, D; Allegrini, P R; Weniger, D; Lütolf, U M; Knuth, A; Yonekawa, Y; Barath, K; Broggini-Tenzer, A; Pruschy, M; Hofer, S (2012). Patupilone (Epothilone B) for recurrent glioblastoma: Clinical outcome and translational analysis of a single-institution phase I/II trial. Oncology, 83(1):1-9.

Goetti, R; Reiner, C S; Knuth, A; Klotz, E; Stenner, F; Samaras, P; Alkadhi, H (2012). Quantitative perfusion analysis of malignant liver tumors: Dynamic computed tomography and contrast-enhanced ultrasound. Investigative Radiology, 47(1):18-24.

Gupta, A; Probst, H C; Vuong, V; Landshammer, A; Muth, S; Yagita, H; Schwender, R; Pruschy, M; Knuth, A; van den Broek, Maries (2012). Radiotherapy promotes tumor-specific effector CD8+ T cells via dendritic cell activation. Journal of Immunology, 189(2):556-566.

Sharma, A; Bode, B; Wenger, R H; Lehmann, K; Sartori, A A; Moch, H; Knuth, A; von Boehmer, L; van den Broek, Maries (2011). Gamma-radiation promotes immunological recognition of cancer cells through increased expression of cancer-testis antigens in vitro and in vivo. PLoS ONE, 6(11):e28217.

Luehty, A; Stenner, F; Lohri, C; Muller, C; Samaras, P; Steiner, R; van den Broek, Maries; Mischo, A; Renner, C; Knuth, A; Ruegg, C; Wenger, R H; Zweifel, M (2011). Autologous Stem Cell Transplantation: Leukapheresis Product has Anti-angiogenic Effects In Vivo Correlating with Neutrophil-derived VEGFR1. Anticancer Research, 31(10):3115-3124.

Karbach, J; Neumann, A; Atmaca, A; Wahle, C; Brand, K; von Boehmer, L; Knuth, A; Bender, A; Ritter, G; Old, L J; Jäger, E (2011). Efficient in vivo priming by vaccination with recombinant NY-ESO-1 protein and CpG in antigen naive prostate cancer patients. Clinical Cancer Research, 17(4):861-870.

Rettig, L; Seidenberg, S; Parvanova, I; Samaras, P; Knuth, A; Pascolo, S (2011). Gemcitabine depletes regulatory T-cells in human and mice and enhances triggering of vaccine-specific cytotoxic T-cells. International Journal of Cancer, 129(4):832-.838.

Bode, P K; Barghorn, A; Fritzsche, F R; Riener, M O; Kristiansen, G; Knuth, A; Moch, H (2011). MAGEC2 is a sensitive and novel marker for seminoma: a tissue microarray analysis of 325 testicular germ cell tumors. Modern Pathology, 24(6):829-835.

Samaras, P; Blickenstorfer, M; Siciliano, R D; Haile, S R; Buset, E M; Petrausch, U; Mischo, A; Honegger, H; Schanz, U; Stüssi, G; Stahel, R A; Knuth, A; Stenner-Liewen, F; Renner, C (2011). Pegfilgrastim reduces the length of hospitalization and the time to engraftment in multiple myeloma patients treated with melphalan 200 and auto-SCT compared with filgrastim. Annals of Hematology, 90(1):89-94.

Samaras, P; Breitenstein, S; Haile, S R; Stenner-Liewen, F; Heinrich, S; Feilchenfeldt, J; Renner, C; Knuth, A; Pestalozzi, B C; Clavien, P A (2011). Selective intra-arterial chemotherapy with floxuridine as second- or third-line approach in patients with unresectable colorectal liver metastases. Annals of Surgical Oncology, 18(7):1924-1931.

Zardavas, D; Meisel, A; Samaras, P; Knuth, A; Renner, C; Pestalozzi, B C; Stenner-Liewen, F (2011). Temsirolimus is highly effective as third-line treatment in chromophobe renal cell cancer. Case Reports in Oncology, 4(1):16-18.

Parvanova, I; Rettig, L; Knuth, A; Pascolo, S (2011). The form of NY-ESO-1 antigen has an impact on the clinical efficacy of anti-tumor vaccination. Vaccine, 29(22):3832-3836.

Samaras, P; Blickenstorfer, M; Haile, S R; Siciliano, D; Petrausch, U; Mischo, A; Zweifel, M; Honegger, H; Schanz, U; Stüssi, G; Taverna, C; Bauer, S; Knuth, A; Stenner-Liewen, F; Renner, C (2011). Validation of prognostic factors and survival of patients with multiple myeloma in a real-life autologous stem cell transplantation setting: a Swiss single centre experience. Swiss Medical Weekly, 141:w13203.

Giger, O; Caduff, R; O'Meara, A; Diener, P A; Knuth, A; Jäger, D; Moch, H; Varga, Z (2010). Frequent expression of the breast differentiation antigen NY-BR-1 in mammary and extramammary Paget's disease. Pathology international, 60(11):726-734.

Speiser, D E; Schwarz, K; Baumgaertner, P; Conzett, K B; Manolova, V; Devevre, E; Sterry, W; Walden, P; Zippelius, A; Senti, G; Voelter, V; Cerottini, J P; Guggisberg, D; Willers, J; Geldhof, C; Romero, P; Kündig, T; Knuth, A; Dummer, R; Trefzer, U; Bachmann, M F (2010). Memory and effector CD8 T-cell responses after nanoparticle vaccination of melanoma patients. Journal of Immunotherapy, 33(8):848-858.

Fischer, E; Kobold, S; Kleber, S; Kubuschok, B; Braziulis, E; Knuth, A; Renner, C; Wadle, A (2010). Cryptic epitopes induce high-titer humoral immune response in patients with cancer. Journal of Immunology, 85(5):3095-3102.

Petrausch, U; Samaras, P; Haile, S R; Veit-Haibach, P; Soyka, J D; Knuth, A; Hany, T F; Mischo, A; Renner, C; Schäefer, N G (2010). Risk adapted FDG-PET/CT-based follow-up in patients with diffuse large B-cell lymphoma after first line therapy. Annals of Oncology, 21(8):1694-1698.

Goetti, R; Leschka, S; Desbiolles, L; Klotz, E; Samaras, P; von Boehmer, L; Stenner, F; Reiner, C; Stolzmann, P; Scheffel, H; Knuth, A; Marincek, B; Alkadhi, H (2010). Quantitative computed tomography liver perfusion imaging using dynamic spiral scanning with variable pitch: feasibility and initial results in patients with cancer metastases. Investigative Radiology, 45(7):419-426.

Rettig, L; Haen, S P; Bittermann, A G; von Boehmer, L; Curioni, A; Krämer, S D; Knuth, A; Pascolo, S (2010). Particle size and activation threshold: a new dimension of danger signaling. Blood, 115(22):4533-4541.

Petrausch, U; Samaras, P; Veit-Haibach, P; Tschopp, A; Soyka, J D; Knuth, A; Hany, T F; Mischo, A; Renner, C; Schaefer, N G (2010). Hodgkin's lymphoma in remission after first-line therapy: which patients need FDG-PET/CT for follow-up? Annals of Oncology, 21(5):1053-1057.

Ospelt, C; Mertens, J C; Jüngel, A; Brentano, F; Maciejewska Rodrigues, H; Huber, L C; Hemmatazad, H; Wüest, T; Knuth, A; Gay, R E; Michel, B A; Gay, S; Renner, C; Bauer, S (2010). Inhibition of fibroblast activation protein and dipeptidylpeptidase 4 increases cartilage invasion by rheumatoid arthritis synovial fibroblasts. Arthritis and Rheumatism, 62(5):1224-1235.

Samaras, P; Heider, H; Haile, S R; Petrausch, U; Schaefer, N G; Siciliano, R D; Meisel, A; Mischo, A; Zweifel, M; Knuth, A; Stenner-Liewen, F; Renner, C (2010). Concomitant statin use does not impair the clinical outcome of patients with diffuse large B cell lymphoma treated with rituximab-CHOP. Annals of Hematology, 89(8):783-787.

Jung, V; Fischer, E; Imig, J; Kleber, S; Nuber, N; Reinshagen, F; Kamradt, J; Grobholz, R; Knuth, A; Renner, C; Wadle, A (2010). Yeast-based identification of prostate tumor antigens provides an effective vaccine platform. Anticancer Research, 30(3):895-902.

Zweifel, M; Stenner-Liewen, F; Weber, A; Samaras, P; Zaugg, K; Knuth, A; Soyka, J D (2010). Increased bone marrow activity on F-18-FDG PET/CT in granulocyte colony stimulating factor producing anaplastic thyroid carcinoma. Clinical Nuclear Medicine, 35(2):103-104.

van den Broek, M; von Boehmer, L; Knuth, A (2010). Developments in cancer immunotherapy. Digestive Diseases, 28(1):51-56.

Samaras, P; Buset, E M; Siciliano, R D; Haile, S R; Petrausch, U; Mischo, A; Honegger, H; Pestalozzi, B C; Schanz, U; Stüssi, G; Stahel, R A; Knuth, A; Renner, C; Stenner-Liewen, F (2010). Equivalence of pegfilgrastim and filgrastim in lymphoma patients treated with BEAM followed by autologous stem cell transplantation. Oncology, 79(1-2):93-97.

Maciejewska Rodrigues, H; Al-Shamisi, M; Hemmatazad, H; Ospelt, C; Bouton, M C; Jäger, D; Cope, A P; Charles, P; Plant, D; Distler, J H W; Gay, R E; Michel, B A; Knuth, A; Neidhart, M; Gay, S; Jüngel, A (2010). Functional autoantibodies against serpin E2 in rheumatoid arthritis. Arthritis and Rheumatism, 62(1):93-104.

Wadle, A; Mischo, A; Strahl, S; Nishikawa, H; Held, G; Neumann, F; Wullner, B; Fischer, E; Kleber, S; Karbach, J; Jager, E; Shiku, H; Odunsi, K; Shrikant, P A; Knuth, A; Cerundolo, V; Renner, C (2010). NY-ESO-1 protein glycosylated by yeast induces enhanced immune responses. FEMS Yeast Research, 27(11):919-931.

Renner, C; Zippelius, A; Riethmüller, G; Knuth, A (2010). Tumorimmunologie. In: Hiddemann, W; Bartram, C R. Die Onkologie. Berlin, Deutschland: Springer Medizin Verlag, 325-345.

Bauer, S; Oosterwijk-Wakka, J C; Adrian, N; Oosterwijk, E; Fischer, E; Wüest, T; Stenner, F; Perani, A; Cohen, L S; Knuth, A; Divgi, C; Jäger, D; Scott, A M; Ritter, G; Old, L J; Renner, C (2009). Targeted therapy of renal cell carcinoma: synergistic activity of cG250-TNF and IFNg. International Journal of Cancer, 125(1):115-123.

Stewart-Jones, G; Wadle, A; Hombach, A; Shenderov, E; Held, G; Fischer, E; Kleber, S; Stenner-Liewen, F; Bauer, S; McMichael, A; Knuth, A; Abken, H; Hombach, A A; Cerundolo, V; Jones, E Y; Renner, C (2009). Rational development of high-affinity T-cell receptor-like antibodies. Proceedings of the National Academy of Sciences of the United States of America (PNAS), 106(14):5784-5788.

Bauer, S; Adrian, N; Siebenborn, U; Fadle, N; Plesko, M; Fischer, E; Wüest, T; Stenner, F; Mertens, J C; Knuth, A; Ritter, G; Old, L J; Renner, C (2009). Sequential cancer immunotherapy: targeted activity of dimeric TNF and IL-8. Cancer Immunity, 9(2):1-10.

Knights, A J; Nuber, N; Thomson, C W; de la Rosa, O; Jäger, E; Tiercy, J M; van den Broek, Maries; Pascolo, S; Knuth, A; Zippelius, A (2009). Modified tumour antigen-encoding mRNA facilitates the analysis of naturally occurring and vaccine-induced CD4 and CD8 T cells in cancer patients. Cancer Immunology, Immunotherapy, 58(3):325-338.

Atmaca, A; Al-Batran, S E; Neumann, A; Kolassa, Y; Jäger, D; Knuth, A; Jäger, E (2009). Whole-body hyperthermia (WBH) in combination with carboplatin in patients with recurrent ovarian cancer - A phase II study. Gynecologic oncology, 112(2):384-388.

Riener, M O; Wild, P J; Soll, C; Knuth, A; Jin, B; Jungbluth, A; Hellerbrand, C; Clavien, P A; Moch, H; Jochum, W (2009). Frequent expression of the novel cancer testis antigen MAGE-C2/CT-10 in hepatocellular carcinoma. International Journal of Cancer, 124(2):352-357.

Mangana, J; Zipser, M C; Conrad, C; Oberholzer, P A; Cozzio, A; Knuth, A; French, L E; Dummer, R (2008). Skin problems associated with pegylated liposomal doxorubicin-more than palmoplantar erythrodysesthesia syndrome. European Journal of Dermatology, 18(5):566-570.

Stenner, F; Liewen, H; Zweifel, M; Weber, A; Tchinda, J; Bode, B; Samaras, P; Bauer, S; Knuth, A; Renner, C (2008). Targeted therapeutic approach for an anaplastic thyroid cancer in vitro and in vivo. Cancer Science, 99(9):1847-1852.

Shebzukhov, Y V; Lavrik, I N; Karbach, J; Khlgatian, S V; Koroleva, B P; Belousov, P V; Kashkin, K N; Knuth, A; Jager, E; Chi, N W; Kuprash, D V; Nedospasov, S A (2008). Human tankyrases are aberrantly expressed in colon tumors and contain multiple epitopes that induce humoral and cellular immune responses in cancer patients. Cancer Immunology, Immunotherapy, 57(6):871-881.

Waibel, R; Treichler, H; Schaefer, N G; van Staveren, D R; Mundwiler, S; Kunze, S; Küenzi, M; Alberto, R; Nüesch, J; Knuth, A; Moch, H; Schibli, R; Schubiger, P A (2008). New derivatives of vitamin B12 show preferential targeting of tumors. Cancer Research, 68(8):2904-2911.

Tinguely, M; Jenni, B; Knights, A; Lopes, B; Korol, D; Rousson, V; Curioni Fontecedro, A; Cogliatti, S B; Bittermann, A G; Schmid, U; Dommann-Scherrer, C; Maurer, R; Renner, C; Probst-Hensch, N M; Moch, H; Knuth, A; Zippelius, A (2008). MAGE-C1/CT-7 expression in plasma cell myeloma: sub-cellular localization impacts on clinical outcome. Cancer Science, 99(4):720-725.

Al-Batran, S E; Hartmann, J T; Probst, S; Schmalenberg, H; Hollerbach, S; Hofheinz, R; Rethwisch, V; Seipelt, G; Homann, N; Wilhelm, G; Schuch, G; Stoehlmacher, J; Derigs, H G; Hegewisch-Becker, S; Grossmann, J; Pauligk, C; Atmaca, A; Bokemeyer, C; Knuth, A; Jäger, E (2008). Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. Journal of Clinical Oncology, 26(9):1435-1442.

Curioni-Fontecedro, A; Knights, A J; Tinguely, M; Nuber, N; Schneider, C; Thomson, C W; von Boehmer, I; Bossart, W; Pahlich, S; Gehring, H; Moch, H; Renner, C; Knuth, A; Zippelius, A (2008). MAGE-C1/CT7 is the dominant cancer-testis antigen targeted by humoral immune responses in patients with multiple myeloma. Leukemia, 22(8):1646-1648.

Theurillat, J P; Zürrer-Härdi, U; Varga, Z; Barghorn, A; Saller, E; Frei, C; Storz, M; Behnke, S; Seifert, Burkhardt; Fehr, M; Fink, D; Rageth, C; Linsenmeier, C; Pestalozzi, B; Chen, Y T; Knuth, A; Jäger, D; Moch, H (2008). Distinct expression patterns of the immunogenic differentiation antigen NY-BR-1 in normal breast, testis and their malignant counterparts. International Journal of Cancer, 122(7):1585-1591.

Heinrich, S; Pestalozzi, B C; Schäfer, M; Weber, A; Bauerfeind, P; Knuth, A; Clavien, P A (2008). Prospective phase II trial of neoadjuvant chemotherapy with gemcitabine and cisplatin for resectable adenocarcinoma of the pancreatic head. Journal of Clinical Oncology, 26(15):2526-2531.

Theurillat, J P; Zürrer-Härdi, U; Varga, Z; Storz, M; Probst-Hensch, N M; Seifert, Burkhardt; Fehr, M K; Fink, D; Ferrone, S; Pestalozzi, B; Jungbluth, A A; Chen, Y T; Jäger, D; Knuth, A; Moch, H (2007). NY-BR-1 protein expression in breast carcinoma: a mammary gland differentiation antigen as target for cancer immunotherapy. Cancer Immunology, Immunotherapy, 56(11):1723-1731.

Theurillat, J P; Ingold, F; Freitag, C; Zippelius, A; Varga, Z; Seifert, Burkhardt; Chen, Y T; Jäger, D; Knuth, A; Moch, H (2007). NY-ESO-1 protein expression in primary breast carcinoma and metastases - correlation with CD8+ T-cell and CD79a+ plasmacytic/B-cell infiltration. International Journal of Cancer, 120(11):2411-2417.

Jäger, E; Gnjatic, S; Nagata, Y; Stockert, E; Jäger, D; Karbach, J; Neumann, A; Rieckenberg, J; Chen, Y T; Ritter, G; Hoffman, E; Arand, M; Old, L J; Knuth, A (2000). Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. Proceedings of the National Academy of Sciences of the United States of America, 97(22):12198-12203.

Jäger, E; Nagata, Y; Gnjatic, S; Wada, H; Stockert, E; Karbach, J; Dunbar, P R; Lee, S Y; Jungbluth, A; Jäger, D; Arand, M; Ritter, G; Cerundolo, V; Dupont, B; Chen, Y T; Old, L J; Knuth, A (2000). Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. Proceedings of the National Academy of Sciences of the United States of America, 97(9):4760-4765.

Jäger, E; Jäger, D; Karbach, J; Chen, Y T; Ritter, G; Nagata, Y; Gnjatic, S; Stockert, E; Arand, M; Old, L J; Knuth, A (2000). Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanoma. Journal of Experimental Medicine, 191(4):625-630.

Jäger, E; Stockert, E; Zidianakis, Z; Chen, Y T; Karbach, J; Jäger, D; Arand, M; Ritter, G; Old, L J; Knuth, A (1999). Humoral immune responses of cancer patients against "Cancer-Testis" antigen NY-ESO-1: correlation with clinical events. International Journal of Cancer, 84(5):506-510.

Stockert, E; Jäger, E; Chen, Y T; Scanlan, M J; Gout, I; Karbach, J; Arand, M; Knuth, A; Old, L J (1998). A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. Journal of Experimental Medicine, 187(8):1349-1354.

Jäger, E; Chen, Y T; Drijfhout, J W; Karbach, J; Ringhoffer, M; Jäger, D; Arand, M; Wada, H; Noguchi, Y; Stockert, E; Old, L J; Knuth, A (1998). Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. Journal of Experimental Medicine, 187(2):265-270.

Jäger, E; Ringhoffer, M; Altmannsberger, M; Arand, M; Karbach, J; Jäger, D; Oesch, F; Knuth, A (1997). Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma. International Journal of Cancer, 71(2):142-147.

Jäger, E; Ringhoffer, M; Arand, M; Karbach, J; Jäger, D; Ilsemann, C; Hagedorn, M; Oesch, F; Knuth, A (1996). Cytolytic T cell reactivity against melanoma-associated differentiation antigens in peripheral blood of melanoma patients and healthy individuals. Melanoma research, 6(6):419-425.

Jäger, E; Ringhoffer, M; Dienes, H P; Arand, M; Karbach, J; Jäger, D; Ilsemann, C; Hagedorn, M; Oesch, F; Knuth, A (1996). Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo. International Journal of Cancer, 67(1):54-62.

Jäger, E; Ringhoffer, M; Karbach, J; Arand, M; Oesch, F; Knuth, A (1996). Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic-T-cell responses: evidence for immunoselection of antigen-loss variants in vivo. International Journal of Cancer, 66(4):470-476.

Jäeger, E; Bernhard, H; Romero, P; Ringhoffer, M; Arand, M; Karbach, J; Ilsemann, C; Hagedorn, M; Knuth, A (1996). Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: implications for tumor vaccines with melanoma-associated antigens. International Journal of Cancer, 66(2):162-169.

This list was generated on Fri Jul 21 05:33:00 2017 CEST.